INTRODUCTION: Patients with ADTKD-MUC1 have one allele producing normal mucin-1 (MUC1) and one allele producing mutant MUC1, which remains intracellular. We hypothesized that ADTKD-MUC1 patients, who have only 1 secretory-competent wild-type MUC1 allele, should exhibit decreased plasma mucin-1 (MUC1) levels. To test this hypothesis, we repurposed the serum CA15-3 assay used to measure MUC1 in breast cancer to measure plasma MUC1 levels in ADTKD-MUC1. METHODS: This cross-sectional study analyzed CA15-3 levels in a reference population of 6,850 individuals, in 85 individuals with ADTKD-MUC1, and in a control population including 135 individuals with ADTKD-UMOD and 114 healthy individuals. RESULTS: Plasma CA15-3 levels (mean ± standard deviation) were 8.6 ± 4.3 U/mL in individuals with ADTKD-MUC1 and 14.6 ± 5.6 U/mL in controls (p < 0.001). While there was a significant difference in mean CA15-3 levels, there was substantial overlap between the 2 groups. Plasma CA15-3 levels were <5 U/mL in 22% of ADTKD-MUC1 patients, in 0/249 controls, and in 1% of the reference population. Plasma CA15-3 levels were >20 U/mL in 1/85 ADTKD-MUC1 patients, in 18% of control individuals, and in 25% of the reference population. Segregation of plasma CA15-3 levels by the rs4072037 genotype did not significantly improve differentiation between affected and unaffected individuals. CA15-3 levels were minimally affected by gender and estimated glomerular filtration rate. DISCUSSION/CONCLUSIONS: Plasma CA15-3 levels in ADTKD-MUC1 patients are approximately 40% lower than levels in healthy individuals, though there is significant overlap between groups. Further investigations need to be performed to see if plasma CA15-3 levels would be useful in diagnosis, prognosis, or assessing response to new therapies in this disorder.

Beth Israel Deaconess Medical Center and Harvard Medical School Boston Massachusetts USA

Biomedical Center and Institute of Microbiology Faculty of Medicine in Pilsen of Charles University Pilsen Czechia

Department of Paediatrics and Inherited Metabolic Disorders Research Unit of Rare Diseases 1st Faculty of Medicine Charles University Prague Czechia

Division of Public Health Sciences Department of Biostatistics and Data Science Wake Forest School of Medicine Winston Salem North Carolina USA

Institute of Medical Biochemistry and Laboratory Diagnostics General University Hospital and the 1st Faculty of Medicine of Charles University Prague Czechia

Renal Electrolyte Division Department of Medicine University of Pittsburgh Pittsburgh Pennsylvania USA

Section on Nephrology Wake Forest School of Medicine Winston Salem North Carolina USA

The Broad Institute of MIT and Harvard Cambridge Massachusetts USA

Zobrazit více v PubMed

Fowler JC, Teixeira AS, Vinall LE, Swallow DM. Hypervariability of the membrane-associated mucin and cancer marker MUC1. Hum Genet. 2003;113((6)):473–9. PubMed

Kirby A, Gnirke A, Jaffe DB, Barešová V, Pochet N, Blumenstiel B, et al. Mutations causing medullary cystic kidney disease type 1 lie in a large VNTR in MUC1 missed by massively parallel sequencing. Nat Genet. 2013;45((3)):299–303. PubMed PMC

Patton S, Gendler SJ, Spicer AP. The epithelial mucin, MUC1, of milk, mammary gland and other tissues. Biochim Biophys Acta. 1995;1241((3)):407–23. PubMed

Sakuma T, Takahashi K, Ohya N, Usuda K, Handa M. Serum KL-6, a novel mucin-like glycoprotein, as an indicator of interstitial pneumonitis following lobectomy. Surg Today. 1999;29((2)):121–8. PubMed

Klee GG, Schreiber WE. MUC1 gene-derived glycoprotein assays for monitoring breast cancer (CA 15-3, CA 27.29, BR): are they measuring the same antigen? Arch Pathol Lab Med. 2004;128((10)):1131–5. PubMed

Li X, Dai D, Chen B, Tang H, Xie X, Wei W. Clinicopathological and prognostic significance of cancer antigen 15-3 and carcinoembryonic antigen in breast cancer: a meta-analysis including 12,993 patients. Dis Markers. 2018;2018:9863092. PubMed PMC

Duffy MJ. CA 15-3 and related mucins as circulating markers in breast cancer. Ann Clin Biochem. 1999;36((Pt 5)):579–86. PubMed

Olinger E, Hofmann P, Kidd K, Dufour I, Belge H, Schaeffer C, et al. Clinical and genetic spectra of autosomal dominant tubulointerstitial kidney disease due to mutations in UMOD and MUC1. Kidney Int. 2020 Sep;98((3)):717–31. PubMed

Devuyst O, Olinger E, Weber S, Eckardt KU, Kmoch S, Rampoldi L, et al. Autosomal dominant tubulointerstitial kidney disease. Nat Rev Dis Primers. 2019;5((1)):60. PubMed

Bleyer AJ, Kmoch S, Antignac C, Robins V, Kidd K, Kelsoe JR, et al. Variable clinical presentation of an MUC1 mutation causing medullary cystic kidney disease type 1. Clin J Am Soc Nephrol. 2014;9((3)):527–35. PubMed PMC

Zivna M, Kidd K, Pristoupilova A, Baresova V, Defelice M, Blumenstiel B, et al. Noninvasive immunohistochemical diagnosis and novel MUC1 mutations causing autosomal dominant tubulointerstitial kidney disease. J Am Soc Nephrol. 2018 PubMed PMC

Yamamoto S, Kaimori JY, Yoshimura T, Namba T, Imai A, Kobayashi K, et al. Analysis of an ADTKD family with a novel frameshift mutation in MUC1 reveals characteristic features of mutant MUC1 protein. Nephrol Dial Transplant. 2017 PubMed

Dvela-Levitt M, Kost-Alimova M, Emani M, Kohnert E, Thompson R, Sidhom EH, et al. Small molecule targets TMED9 and promotes lysosomal degradation to reverse proteinopathy. Cell. 2019;178((3)):521–e23. PubMed

Bleyer AJ, Kmoch S, Greka A. Diagnostic utility of exome sequencing for kidney disease. N Engl J Med. 2019;380((21)):2080. PubMed

Blumenstiel B, Defelice M, Birsoy O, Bleyer AJ, Kmoch S, Carter TA, et al. Development and validation of a mass spectrometry-based assay for the molecular diagnosis of mucin-1 kidney disease. J Mol Diagn. 2016;18((4)):566–71. PubMed

Janssen R, Kruit A, Grutters JC, Ruven HJ, Gerritsen WB, van den Bosch JM. The mucin-1 568 adenosine to guanine polymorphism influences serum Krebs von den Lungen-6 levels. Am J Respir Cell Mol Biol. 2006;34((4)):496–9. PubMed

Li X, Xu Y, Zhang L. Serum CA153 as biomarker for cancer and noncancer diseases. Prog Mol Biol Transl Sci. 2019;162:265–76. PubMed

Rani BS, Suchitra MM, Srinivasa Rao PVLN, Kumar VS. Serum tumor markers in advanced stages of chronic kidney diseases. Saudi J Kidney Dis Transpl. 2019 Jul-Aug;30((4)):898–904. PubMed

Ng W, Loh AX, Teixeira AS, Pereira SP, Swallow DM. Genetic regulation of MUC1 alternative splicing in human tissues. Br J Cancer. 2008;99((6)):978–85. PubMed PMC

Karczewski KJ, Francioli LC, Tiao G, Cummings BB, Alföldi J, Wang Q, et al. The mutational constraint spectrum quantified from variation in 141,456 humans. Nature. 2020;581((7809)):434–43. PubMed PMC

Hanisch FG, Kinlough CL, Staubach S, Hughey RP. MUC1 membrane trafficking: protocols for assessing biosynthetic delivery, endocytosis, recycling, and release through exosomes. Methods Mol Biol. 2012;842:123–40. PubMed

Pratt WS, Islam I, Swallow DM. Two additional polymorphisms within the hypervariable MUC1 gene: association of alleles either side of the VNTR region. Ann Hum Genet. 1996;60((Pt 1)):21–8. PubMed

Horimasu Y, Ishikawa N, Tanaka S, Hirano C, Iwamoto H, Ohshimo S, et al. MUC1 in lung adenocarcinoma: cross-sectional genetic and serological study. BMC Cancer. 2017;17((1)):263. PubMed PMC

Wenzel A, Altmueller J, Ekici AB, Popp B, Stueber K, Thiele H, et al. Single molecule real time sequencing in ADTKD-MUC1 allows complete assembly of the VNTR and exact positioning of causative mutations. Sci Rep. 2018;8((1)):4170. PubMed PMC

Bleyer AJ, Kidd K, Robins V, Martin L, Taylor A, Santi A, et al. Outcomes of patient self-referral for the diagnosis of several rare inherited kidney diseases. Genet Med. 2019 PubMed PMC

Stevens LA, Schmid CH, Greene T, Zhang YL, Beck GJ, Froissart M, et al. Comparative performance of the CKD epidemiology collaboration (CKD-EPI) and the modification of diet in renal disease (MDRD) study equations for estimating GFR levels above 60 mL/min/1.73 m2. Am J Kidney Dis. 2010;56((3)):486–95. PubMed PMC

Zeger SL, Liang KY, Albert PS. Models for longitudinal data: a generalized estimating equation approach. Biometrics. 1988;44((4)):1049–60. PubMed

Berk R. Statistical learning from a regression perspective. Switzerland: Springer International Publisher; 2016.

Eight-fold increased COVID-19 mortality in autosomal dominant tubulointerstitial kidney disease due to MUC1 mutations: an observational study

A Novel Monoallelic ALG5 Variant Causing Late-Onset ADPKD and Tubulointerstitial Fibrosis

Autosomal dominant tubulointerstitial kidney disease: A review

The utility of a genetic kidney disease clinic employing a broad range of genomic testing platforms: experience of the Irish Kidney Gene Project